Health CareHealth Care Equipment & Services
  • Price (USD)74.46
  • Today's Change-0.69 / -0.92%
  • Shares traded6.99m
  • 1 Year change-7.46%
  • Beta0.6650
Data delayed at least 15 minutes, as of Aug 05 2021 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s products include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery and acute therapies. Its renal care offering includes peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services. Its medication delivery offerings include intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices. Its pharmaceuticals offerings include premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services. Its clinical nutrition offerings include parenteral nutrition (PN) therapies and related products. Its advanced surgery offerings include biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention. It also offers polysaccharide hemostatic system (PerClot) products.

  • Revenue in USD (TTM)12.20bn
  • Net income in USD1.12bn
  • Incorporated1931
  • Employees50.00k
  • Location
    Baxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
  • Phone+1 (847) 948-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.baxter.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BAX:NYQ since
Hill-Rom Holdings IncRumoured28 Jul 202128 Jul 2021Rumoured-9.32%--
Omnicell IncRumoured08 Dec 202008 Dec 2020Rumoured-4.26%--
Data delayed at least 15 minutes, as of Aug 05 2021 21:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Hologic, Inc.5.66bn2.04bn19.41bn5.81k9.825.008.033.437.807.8021.6915.310.73573.856.78973,959.4026.434.2332.355.1368.8754.6635.939.481.3131.720.44760.0012.156.90661.5353.3311.84--
Cooper Companies Inc2.66bn2.36bn20.40bn12.00k8.743.317.687.6747.3947.3953.63125.260.34271.636.19221,650.0030.346.2334.877.1164.7663.6688.5414.520.74638.190.21990.8652-8.396.23-
Zimmer Biomet Holdings Inc7.89bn935.00m30.90bn20.00k33.122.4615.473.924.484.3937.7060.270.32960.92056.35394,445.003.921.154.391.2970.6670.6511.903.820.96436.300.384366.54-12.003.21-112.27---1.161.76
West Pharmaceutical Services Inc.2.52bn519.20m31.67bn9.20k62.5715.5951.8412.566.846.8433.2227.470.94734.936.14274,184.8018.6311.0122.1613.0139.3533.2819.6712.682.3972.830.111118.3316.698.9343.2429.355.797.63
Baxter International Inc12.20bn1.12bn37.57bn50.00k34.464.4218.863.082.182.1823.7416.990.62313.716.25243,940.005.7810.836.8913.3139.5741.889.2717.191.7812.870.419520.452.743.2136.5622.90-4.89-5.54
ResMed Inc.3.09bn457.24m39.75bn7.77k87.4414.6764.5612.863.123.1221.1718.620.67963.075.62397,820.6010.0512.6211.9314.7558.1657.7114.7918.461.1220.720.212545.4413.4411.9951.4111.998.056.85
DexCom, Inc.2.17bn530.60m49.78bn5.50k96.3624.9181.1022.945.345.3421.8220.660.54072.695.56394,527.3013.225.7815.116.7869.9666.0924.457.985.254.020.46950.0030.5436.81388.23--42.98--
Align Technology, Inc.3.47bn698.45m56.03bn18.07k80.6916.5697.6816.138.778.7743.6642.770.73755.775.42192,265.8014.8329.3220.5942.4474.2773.2820.1033.471.21----0.002.7123.93301.0865.2723.72--
Data as of Aug 05 2021. Currency figures normalised to Baxter International Inc's reporting currency: US Dollar USD

Institutional shareholders

43.23%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Mar 202151.11m10.16%
The Vanguard Group, Inc.as of 31 Mar 202136.87m7.33%
BlackRock Fund Advisorsas of 31 Mar 202126.64m5.30%
Morgan Stanley Investment Management Ltd.as of 31 Mar 202123.49m4.67%
Generation Investment Management LLPas of 31 Mar 202120.98m4.17%
SSgA Funds Management, Inc.as of 31 Mar 202120.52m4.08%
Veritas Asset Management LLPas of 31 Mar 202111.21m2.23%
Capital Research & Management Co. (World Investors)as of 31 Mar 20219.64m1.92%
Capital Research & Management Co. (International Investors)as of 31 Mar 20218.98m1.79%
The Caisse de d�p�t et placement du Qu�becas of 31 Mar 20217.92m1.58%
More ▼
Data from 31 Mar 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.